[{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Cowen"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Jefferies"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Oxford Finance LLC","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Oxford Finance LLC","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Oxford Finance LLC"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Immunology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"Immunoproteasome","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Kezar Life Sciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0.13,"dosageForm":"Injectable\/Injection","sponsorNew":"Kezar Life Sciences \/ Everest Medicines","highestDevelopmentStatusID":"8","companyTruncated":"Kezar Life Sciences \/ Everest Medicines"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Kezar Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Kezar Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Kezar Life Sciences"},{"orgOrder":0,"company":"Everest Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Nephrology","graph2":"Phase II","graph3":"Everest Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Everest Medicines \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Everest Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kezar Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Kezar Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Zetomipzomib","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kezar Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kezar Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kezar Life Sciences \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for Zetomipzomib
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Autoimmune Hepatitis.
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor. It is currently being evaluated for the treatment of Lupus Nephritis.
Details :
Under the agreement, Everest will develop and commercialize KZR-616 (zetomipzomib), Kezar’s novel, first-in-class selective immunoproteasome inhibitor, in Greater China, South Korea and Southeast Asia.
Details :
KZR-616 (zetomipzomib) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Details :
KZR-616 (zetomipzomib), a first-in-class inhibitor of the immunoproteasome, has potent anti-inflammatory effects. Zetomipzomib continued to be well-tolerated over the course of the 37-week study, demonstrating a favorable safety and tolerability profile.
Details :
Zetomipzomib (KZR-616) is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases.
Reset All
